CSX Sell-Off Deemed Overdone and 4 Stock Analyses to Note

CSX Corp. (NYSE:CSX): According to Jefferies, the sell-off in CSX shares yesterday due to Norfolk Southern’s (NYSE:NSC) guidance was overdone. The firm does not believe that CSX’s quarter will be as bad as Norfolk’s, and it has decided to keep a Buy rating on the stock.

Don’t Miss: Despite Maps Snafu, Apple Apps Make Bank.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): After the survey of 100 oncologists, RBC Capital has decided to raise confidence in the company’s launch of its Ponatinib drug and the possibility of its ’113 treatment. The firm has decided to keep its Outperform rating on the stock.

Oracle Corp. (NASDAQ:ORCL) reported in-line Q1 results, causing RBC Capital to believe that Oracle’s stock will see a boost due to solid software demand, expected hardware growth, and moderating comps through the next few quarters. The firm keeps its Outperform rating and a $36 target on the stock.

Avago Technologies Limited (NASDAQ:AVGO): According to Lazard Capital, the pullbacks in Avago (AVOG) and Qualcomm (NASDAQ:QCOM) shares yesterday, which occurred to sympathize with Skyworks (NASDAQ:SWKS), are mostly unjustified. Skyworks’ shortfall is attributed to company-specific share shifts in 2G China, and the firm keeps its Buy ratings on Avago and Qualcomm.

Incyte Corporation (NASDAQ:INCY): After it attended the Midwest myeloproliferative neoplasm patient symposium, JMP Securities thinks that the conditions of myelofibrosis patients who use Incyte’s Jakafi have shown a quick improvement. The firm reports that the discontinuation rate of the drug is starting to ease while doctors continue to gain experience with the treatment, and JMP Securities keeps its Outperform rating and a $28 target on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>